Bristol-Myers Squibb Acquires Cancer Specialist, Flexus, for $800m

Bristol-Myers Squibb have announced that they will be acquiring Flexus Biosciences in an agreement worth up to $1.25 billion. Flexus are a biotechnology company which specialises in the discovery, development, and commercialisation of small-molecule cancer immunotherapies targeting regulatory T cells. The acquisition will involve an $800 million upfront payment, giving Bristol-Myers Squibb full rights to

Continue Reading

Roche Acquires Signature Diagnostics

Roche has today announced that they have acquired Germany’s Signature Diagnostics. Signature Diagnostics were a privately-held translational oncology and genomics company, based in Potsdam, Germany. The acquisition is the fifth deal that Roche has made within the past year, aimed at building their molecular diagnosis business. Signature Diagnostics focuses on developing large blood plasma and

Continue Reading

Only Medics Referral Scheme

Only Medics, part of the Clinical Professionals Group, have launched a new online referral form, allowing people to easily refer a friend or colleague who may be looking for a new job within life sciences. The Clinical Professionals Group offers a generous referral scheme of £250 vouchers (or the European equivalent) for anyone who refers

Continue Reading

Physician2Pharma Event a Success

Earlier this month Only Medics, part of the Clinical Professionals Group, held their annual Physician2Pharma recruitment event for NHS medics looking to transition into the pharmaceutical industry. The event was invite only and attended by 40 people comprising of hand picked GMC registered physicians looking to make the transition from the NHS into the pharmaceutical

Continue Reading

AstraZeneca Confident of Reaching $45bn Sales by 2023

AstraZeneca have confirmed that they remain confident of generating annual sales of over $45 billion by 2023. The increase is expected as a result of accelerating growth momentum from both AstraZeneca’s existing products and those currently awaiting market approval. Five current growth platforms (diabetes, Brilinta, respiratory, Emerging Markets and Japan) currently account for over half

Continue Reading

AstraZeneca Acquires Definiens

AstraZeneca has announced that they are acquiring tissue sample specialist, Definiens, increasing their oncology efforts. AstraZeneca’s MedImmune unit is paying an initial $150 million, followed by additional predetermined milestone payments, to acquire Definiens.  AstraZeneca noted that Definiens has “pioneered a world-leading imaging and data analysis technology, known as Tissue Phenomics, which dramatically improves the identification

Continue Reading

Bristol-Myers Squibb Announce Positive Q3 Results

Bristol-Myers Squibb have announced positive third quarter results for 2014, beating earlier forecasts after stronger-than-expected revenues for the period. The biopharmaceutical company posted earnings on Friday of $721 million, or $0.43 a share, an increase from earnings of $692 million, or $0.42 per share, in Q3 of 2013.  Once adjusted for special items, Bristol-Myers Squibb’s

Continue Reading